Market capitalization | $400.00k |
Enterprise Value | $14.42m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.31 |
P/S ratio (TTM) P/S ratio | 0.01 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -7.44% |
Revenue (TTM) Revenue | $46.03m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast BIOLASE, Inc.:
1 Analyst has issued a forecast BIOLASE, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 46 46 |
7%
7%
|
|
Gross Profit | 16 16 |
6%
6%
|
|
EBITDA | -11 -11 |
43%
43%
|
EBIT (Operating Income) EBIT | -14 -14 |
37%
37%
|
Net Profit | -16 -16 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
Head office | United States |
CEO | John Beaver |
Employees | 157 |
Founded | 1987 |
Website | www.biolase.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.